Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant DCF plus adjuvant S-1 for locally advanced esophageal cancer with nodal metastasis
jRCTs031180375Phase 2Recruiting
- Start
- Aug 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin, fluorouracil and tegafur in esophageal cancer. Primary endpoint: Recurrence-free survival. Started Aug 2017; status: recruiting.
02
Drugs
docetaxelcisplatinfluorouraciltegafur
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031180375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180375.